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Objectives: Our aim was to evaluate the safety and efﬁcacy
of ipilimumab combined with standard ﬁrst-line chemo-
therapy for patients with extensive-stage SCLC.
Methods: Patients with chemotherapy-naive extensive-
stage SCLC were treated with carboplatin and etoposide for
up to six cycles. Ipilimumab, 10 mg/kg, was given on day 1*Corresponding author.
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September 2011 and April 2014; 39 were evaluable for
safety and 38 for efﬁcacy. Six of 38 patients (15.8% [95%
conﬁdence interval (CI): 7.4–30.4]) were alive and
progression-free at 1-year by RECIST. Median PFS was 6.9
months (95% CI: 5.5–7.9). Median immune-related PFS was
7.3 months (95% CI: 5.5–8.8). Median overall survival was
17.0 months (95% CI: 7.9–24.3). Of the patients evaluable
for response, 21 of 29 (72.4%) achieved an objective
response by RECIST and 28 of 33 (84.8%) achieved an
objective response by the immune-related response criteria.
All patients experienced at least one adverse event; at least
one grade 3 or higher toxicity developed in 35 of 39 pa-
tients (89.7%); in 27 patients (69.2%) this was related to
ipilimumab. Five deaths were reported to be related to
ipilimumab. Positivity of an autoimmune proﬁle at baseline
was associated with improved outcomes and severe
neurological toxicity.
Conclusions: Ipilimumab in combination with carboplatin
and etoposide might beneﬁt a subgroup of patients with
advanced SCLC. Autoantibody analysis correlates with
treatment beneﬁt and toxicity and warrants further
investigation.
 2016 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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SCLC accounts for approximately 15% to 20% of all
lung cancers. Despite the high percentage of initial re-
sponses to chemotherapy, overall prognosis remains
dismal, with median survival times of 9.5 months for
extensive-stage disease.1 No therapeutic strategy except
for the addition of radiotherapy to chemotherapy has
produced improvements in survival.2–7
Harnessing the immune response to attack tumor
cells with antibodies directed against checkpoint mole-
cules has had dramatic impact in the treatment of mel-
anoma8,9 and other solid tumors.10,11
Clinical evidence supports immune recognition of
SCLC in the form of paraneoplastic immune-mediated
syndromes (PNSs). PNSs are associated with the cross-
reactivity of immune responses with self-antigens,
which are frequently neuronal antigens physiologically
expressed by the normal nervous system and ectopically
by cancer cells,12 but the T-cell–based mechanisms for
paraneoplastic events remain poorly understood.13 The
presence of autoimmune disease seems to be associatedwith better outcomes.14,15 These ﬁndings suggest that
the effective antitumor immune responses are linked to
autoimmune manifestations.16
Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is
expressed by lymphocytes early in the adaptive immune
response, and it binds to B7 expressed in antigen-
presenting cells to down-regulate T-cell responses.17
Additionally, CTLA-4 is highly expressed on regulatory
T-cells, and antibody binding to CTLA-4 leads to their
removal by antibody-dependent cytotoxicity.18 Release
of these “brakes” with anti–CTLA-4 antibodies has been
successfully tested in several tumors.
Ipilimumab is an anti–CTLA-4 antibody approved for
the treatment of metastatic melanoma.8,19,20 However,
how effective ipilimumab is in rapidly progressing tu-
mors such as SCLC is unclear. However, chemotherapy
for SCLC is effective in killing tumor cells, and cell death
will release tumor antigen.21 It is therefore possible that
in the context of immune modulation with ipilimumab,
recognition of these antigens might induce clinically
useful antitumor immunity.
In 2013, a study assessing ipilimumab added to carbo-
platin and paclitaxel by randomizing patients with
extensive-stage SCLC to chemotherapy only or chemothe-
rapy with concurrent or phased ipilimumab was publi-
shed.22 This study suggested that phased ipilimumab after
two cycles of chemotherapy was a promising strategy.
The current study enrolled patients with extensive-
stage SCLC treated with standard carboplatin and eto-
poside in the ﬁrst-line setting and aimed to evaluate the
safety and efﬁcacy of ipilimumab added to this combi-
nation and explore predictive biomarkers (ClinicalTrials.
gov identiﬁer NCT01331525).Patients and Methods
Patient Population
The patients were men and women aged 18 and older
who had a histological or cytological diagnosis of SCLC;
no previous systemic therapy for SCLC; an Eastern
Cooperative Oncology Group performance status of 0 or
1; adequate baseline laboratory test results; and no
active or chronic infection with human immunodeﬁ-
ciency virus, hepatitis B, or hepatitis C. Exclusion criteria
included limited-stage SCLC appropriate for radical
treatment with chemoirradiation, symptomatic central
nervous system metastases, or autoimmune disease; a
history of live vaccines (for up to 1 month before or after
any dose of ipilimumab); and a history of prior treatment
with a CD137 agonist or CTLA-4 inhibitor or agonist and
concomitant therapy with any of the following:
interleukin-2, interferon, or other immunotherapy regi-
mens; immunosuppressive agents; other investigational
therapies; and chronic use of systemic corticosteroids.
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This single-stage nonrandomized phase II study
examined the efﬁcacy and toxicity of ipilimumab (10
mg/kg) together with carboplatin (area under the
curve ¼ 6, intravenously [IV] on day 1) and etoposide
(120 mg/m2 IV on day 1 and 100 mg twice a day orally
on days 2 and 3 every 21 days) (ICE). Patients could
enroll in the trial at any point until cycle 3. Patients
received carboplatin and etoposide up to six cycles.
Chemotherapy was discontinued in the event of
progressive disease (PD) (according to the Response
Evaluation Criteria in Solid Tumors [RECIST], version [v]
1.0) or excessive toxicity. Ipilimumab, 10 mg/kg, was
given IV on day 1 of chemotherapy cycles 3 to 6 and then
once every 12 weeks from week 30 until immune-
related disease progression or excessive toxicity.
Patients could be offeredprophylactic cranial irradiation
(PCI) after completion of induction chemoimmunotherapy.
The trial was conducted in accordance with good
clinical practice, and ethical approval was obtained
(Multicenter Research Ethics Committee 10/H0502/95;
International Standard Randomized Controlled Trials
Number: 14095893); written informed consent was
provided by all patients before enrollment.Study Assessments
Tumor assessments were conducted by computer-
ized tomography every 6 weeks for the ﬁrst year (until
week 54) and then every 12 weeks until disease pro-
gression by both RECIST, v 1.0, and immune response
criteria (irRC).23 A baseline brain computerized tomog-
raphy scan (not a magnetic resonance imaging scan) was
performed for central nervous system disease evaluation
if clinically indicated.
Patients who received at least one dose of ipilimumab
were consideredevaluable for safety andassessedusing the
National Cancer Institute CommonTerminologyCriteria for
Adverse Events (CTCAE), v. 4.0 (http://ctep.cancer.gov). As
no safetydatawereavailable for thecombination, a planned
interim safetymonitoring assessmentwasperformed.Once
nine patients had been treated with the combination for at
least 6 weeks, a ﬁrst clinical safety assessment was per-
formed to identify any early safety signals from ipilimumab
given in combination with carboplatin and etoposide. In
addition, a review of safety was triggered throughout the
trial if a grade 3 (G3) or higher toxicity thought to be related
to the study drugs developed in at least 40% of the patients
treated, if at least 10% of patients experienced an unex-
pected ipilimumab-related G3 or higher toxicity that could
not be alleviated or controlled by appropriate care and/or
steroid and/or inﬂiximab therapy within 14 days of the
initiation of such therapy, or in response to any ipilimumab-
related deaths unless attributed to disease progression.Data on adverse events (AEs) and immune-related
AEs (irAEs) were collected at each study visit and until
90 days after the last dose of ipilimumab; irAE was
deﬁned as an AE that was treatment related and
considered to be immune mediated.
All irAEs were managed according to international
guidelines and package inserts/product labels. No dose
reductions were allowed for ipilimumab. Dose modiﬁ-
cations for carboplatin and etoposide were made ac-
cording to local practice.
Biomarker Assessment
Detection of autoantibodies was performed at baseline
and during follow-up in cases where clinically indicated.
Anti-VGCCand anti-VGKCantibodiesweredeterminedwith
radioimmunoprecipitation assays.24,25 Antibodies against
intracellular neuronal antigens were detected using indi-
rect immunohistochemistry on primate cerebellum (NOVA
Lite, Inova, Werfen, Warrginton, UK), immunoblotting
(RavoPNSBlot,RravoDiagnostika, Freiberg, Germany), and
a semiautomated enzyme-linked immunosorbent assay.26
Interpretationwas done according to protocol instructions.
Statistical Analysis
The sample size was based on A’Hern’s single-stage
phase II design, with a two-sided signiﬁcance level of
0.05, 80% power, p0 (clinically uninteresting true
progression-free survival [PFS] according to RECIST, v
1.0) ¼ 10%, and p1 (sufﬁciently promising true PFS ac-
cording to RECIST v 1.0) ¼ 25%. The design required
recruiting 40 evaluable patients, and the efﬁcacy of the
treatmentwas consideredworthdeveloping further if eight
or more patients were alive and progression-free at 1 year.
The intention-to-treat population consisted of all
registered patients. Toxicity was assessed using the
safety population, which excluded patients who did not
receive any ipilimumab. Baseline, treatment and efﬁcacy
information was performed on the efﬁcacy analysis
population, which consisted of all eligible patients
included in the safety population.
Outcome Analysis
The primary end point was 1-year PFS according to
RECIST v 1.0. PFS was deﬁned as the time from day 1 of
the ﬁrst cycle of chemotherapy to the date of progression
or death from any cause.
Secondary end points included PFS; PFS by irRC
(irPFS); overall survival (OS) deﬁned as the time from
the date of day 1, cycle 1 of chemotherapy to the date of
death from any cause; best overall response deﬁned as
the maximum response by RECIST v 1.0 compared with
the baseline scan at study entry; duration of response
deﬁned as the time from ﬁrst response by RECIST v 1.0
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of response by irRC; and toxicity assessment according
to the National Cancer Institute Common Terminology
Criteria for Adverse Events, v 4.0.
Patients who had not died or progressed were
censored for survival end points at the last documented
clinical review. Survival analyses were performed using
Kaplan-Meier estimates, and 95% conﬁdence intervals
(CIs) for proportions were calculated using the Wilson
interval as recommended for small n by Brown et al.27
Summary statistics and plots were used to examine other
secondary end points and characterize response rates.Figure 1. CONSORT diagram showing the disposition of patient
ITT, intention to treat.Immunological data were recorded for each patient.
Ad hoc exploratory analysis was carried out to assess
associations between antibody positivity and clinical
outcomes (irRC, irPFS, OS, and toxicity occurrence).Results
Patients and Treatment
Forty-two patients with no previous systemic therapy
for SCLC were registered into this study between
September 2011 and April 2014 at six sites in the United
Kingdom (Fig. 1). Three patients withdrew from the trials in the ICE (ipilimumab, carboplatin, and etoposide) study.
Table 2. Autoantibody Analysis at Baseline in the Efﬁcacy
Population (n ¼ 38)
Autoantibody Assays n (%)
Anti-SOX2
Positive 9 (23.7)
Negative 29 (76.3)
Not performed/missing 0
Anti-Hu
Positive 6 (15.8)
Negative 32 (84.2)
Not performed/missing 0
Anti-Yo
Positive 2 (6.5)
Negative 29 (93.5)
Not performed/missing 7
Anti-VGCCA
September 2016 Ipilimumab, Carboplatin, Etoposide in SCLC 1515before receiving ipilimumab, and atypical carcinoid was
retrospectively diagnosed in one patient. Baseline de-
mographics and disease characteristics are shown in
Table 1 for the evaluable population (n ¼ 38). Most
patients were male (66%), with a performance status
(PS) of 1 (66%) and involvement of the lung, lymph
nodes, and liver. The presence of autoantibodies was
investigated at baseline in 38 patients (Table 2). Seven-
teen patients (45%) had at least one conﬁrmed positive
autoimmune antibody at baseline.
At the ﬁnal database lock (November 3, 2015) after a
minimum follow-up of 6.8 months (median 8.5 months)
no patients were still receiving treatment.
The main reason for discontinuation of treatment
was toxicity (10 of 39 [26%]).Table 1. Baseline Patient Demographics and Disease
Characteristics of the Efﬁcacy Population (n ¼ 38)
Demographic or Disease Characteristics Value
Age, y
Median 63
Range 44–84
Sex, % (n)
Female 13 (34.2)
Male 25 (65.8)
ECOG PS, n (%)
0 11 (34.4)
1 21 (65.6)
Missing 6
Index and nonindex lesions, n (%)
Lung 27 (71.1)
Lymph node 27 (71.1)
Liver 15 (39.5)
Bone 3 (7.9)
CNS 1 (2.6)
Effusion 2 (5.3)
Soft tissue 7 (18.4)
Other 13 (34.2)
LDH (IU/L)
Median 398
Range 186–1252
Missing 4
IgG (g/L)
Median 8.10
Range 0–18.00
Not performed/missing 3
IgA(g/L)
Median 2.20
Range 0.70–4.20
Not performed/missing 4
IgM(g/L) 0.75
Median 0.20–2.60
Range 4
Note: Denominator is nonmissing data for the analysis population for each
test performed.
ECOG PS, Eastern Cooperative Oncology Group performance status; CNS,
central nervous system; LDH, lactate dehydrogenase; IgG, immunoglobulin G;
IgA, immunoglobulin A; IgM, immunoglobulin M.
Positive 0
Negative 24 (100)
Not performed/missing 14
Anti-VGPCA
Positive 2 (8.3)
Negative 22 (91.7)
Not performed/missing 14
Thyroid peroxidase
Positive 4 (16.0)
Negative 21 (84.0)
Not performed/missing 13
Rheumatoid factors
Positive 3 (12.5)
Negative 21 (87.5)
Not performed/missing 14
Antimuscle antibodies
Positive 0
Negative 33 (100)
Not performed/missing 5
ANA
Positive 10 (28.6)
Negative 25 (71.4)
Not performed/missing 3
ANCA
Positive 2 (8.3)
Negative 22 (91.7)
Not performed/missing 14
Note: Denominator is nonmissing data for the analysis population for each
test performed.
SOX2, SRY-box 2; anti-Hu, anti-human; anti-Yo, purkinje cell cytoplasmic
antibody type 1; VGCCA, voltage-gated calcium channel antibody; VGPCA,
anti-voltage gated potassium channel antibody; ANA, antinuclear antibody;
ANCA, antineutrophil cytoplasmic antibody.Thirty-seven of 38 patients started ipilimumab
treatment on the third cycle of chemotherapy. The me-
dian number of cycles of the combination treatment for
the efﬁcacy analysis population (n ¼ 38) was six (range
3–6). Of these patients, 24 (63%) completed the che-
moimmunotherapy phase. Twenty-three patients (61%)
had at least one chemotherapy dose delayed and 15
(40%) had dose modiﬁcations. Fifteen patients (40%)
had at least one dose of ipilimumab delayed and 13
(34%) missed at least one dose during the combination
1516 Arriola et al Journal of Thoracic Oncology Vol. 11 No. 9phase. The number of patients who received at least one
maintenance dose of ipilimumab was nine (24%), and
one patient received treatment for 78 weeks.
Nine patients (24%) received PCI and eight (21%)
received radiotherapy to the chest.Efﬁcacy
Of the 38 patients (the efﬁcacy analysis population),
six (15.8% [95% CI: 7.4%–30.4%]) were progression-
free at 1 year by RECIST. Median PFS was 6.9 months
(95% CI: 5.5–7.9) (Fig. 2). Median irPFS was 7.3 months
(95% CI: 5.5–8.8) with an irPFS at 1 year of 12.6% (95%
CI: 4.0–26.3). Median OS was 17.0 months (95% CI: 7.9–
24.3) (Fig. 3). Response information by RECIST and irRC
was available for 29 and 33 patients, respectively, 21 of
whom (72.4%) achieved an objective response according
to RECIST and 28 of whom (84.8%) achieved an objective
response according to irRC (Table 3). Supplementary
Table 1 compares both patterns of response.
Patients receiving PCI had a numerically superior
OS (median OS 18.5 versus 12.3 months, respectively),
but this difference did not reach statistical signiﬁcance
(p ¼ 0.447).Figure 2. Kaplan-Meier plots for progression-free survival
(PFS) according to the Response Evaluation Criteria in Solid
Tumors (RECIST), version 1.0, (A) and immune-related
response criteria (B) and according to autoantibody status
at baseline (C). CI, conﬁdence interval; irRC, immune-
related response criteria; NR, not reached.Safety
All toxicities are listed in Supplementary Table 2.
Table 4 summarizes the incidence of treatment related
G3 or higher AEs for the safety analysis population
(n ¼ 39). All patients experienced at least one AE. At
least one G3 or higher toxicity developed in 35 (90%); in
27 (69%) this toxicity was thought to be related to
ipilimumab. Neurological AEs were reported for 19 pa-
tients (49%), although only four patients (10%) experi-
enced ﬁve high-grade AEs and three (8%) of these were
related to ipilimumab. Central neuropathies (described
as mild encephalopathy and cerebellar syndromes
mimicking PNS) developed in two patients and one had
severe headaches with deterioration of performance
status. No association was observed between the
occurrence of neurological toxicity and PCI treatment.
Other frequent AEs (probably irAEs) were diarrhea
in 28 patients (72%) and skin rash in 20 patients
(51%), respectively. For 18 patients (46%), treatment
delays were associated with ipilimumab-related
toxicity. Five deaths (13%) were reported to be
related to ipilimumab. Two of the deaths (due to cardiac
arrest and neutropenic sepsis) happened while the pa-
tients where receiving treatment or shortly thereafter,
but the remaining three (due to pneumonia, autoim-
mune encephalitis, and sepsis) happened 4 to 5 months
after the last treatment.
In an unplanned analysis, we evaluated whether
severity of irAEs was associated with outcome. Patientswho had more severe (G3) irAEs had numerically
worse OS (Supplementary Fig. 1), but this was not sta-
tistically signiﬁcant. Moreover, 73% of patients with
grade 1 or 2 irAEs were alive at 1 year compared with
47% of patients with severe (G3) irAEs.
Figure 3. Kaplan-Meier plots for overall survival (A) and ac-
cording to autoantibody status at baseline (B). OS, overall
survival; CI, conﬁdence interval.
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In an ad hoc analysis, we explored the association
between positivity of autoantibodies at baseline and
clinical outcomes.Table 3. Best Overall Tumor Response in the Efﬁcacy
Population (n ¼ 38)
Tumor response Value
RECIST version 1.0
Complete response 1 (3.4%)
Partial response 20 (69.0%)
Stable disease 3 (10.3%)
Progressive disease 5 (17.2%)
Not assessed/missing 9
Immune-related response criteria
Complete response 2 (6.1%)
Partial response 26 (78.8%)
Stable disease 5 (15.2%)
Progressive disease 0
Not assessed/missing 5
RECIST, Response Evaluation Criteria in Solid Tumors.The most frequently detected antibodies were anti-
nuclear antibodies in 10 patients and anti–SRY-box 2
(SOX2) in nine patients (Table 2). Twenty-three patients
(60.5%) had at least one positive autoantibody detec-
tion. Antineuronal antibodies were more frequently
positive (44.7%) than were the rest of the autoanti-
bodies (31.6%). We assessed the association between
autoantibodies and response (according to irRC). We
found that none of 14 patients with positive anti-
neuronal antibodies versus ﬁve of 19 patients with no
positivity showed immune-related stable disease or
immune-related PD (p ¼ 0.049). Any autoantibody pos-
itivity showed a trend to association with response
(p ¼ 0.066).We then evaluated the association between
autoantibody positivity and irPFS. We observed that
patients with any positive autoantibody detected at
baseline experienced a signiﬁcantly longer median irPFS
(8.8 months [95% CI: 5.1–10.7] versus 7.3 months [95%
CI: 2.9–7.9, p ¼ 0.036] (Fig. 2C). Antinuclear antibody
positivity predicted for a signiﬁcantly prolonged irPFS
(10.2 months versus 6.9 months [p ¼ 0.032]). Patients
with any positive autoimmune antibody showed a trend
to prolonged survival (18.5 months versus 17 months
[p ¼ 0.144]) (Fig. 3B).
We assessed the correlation between autoantibodies
and toxicity. We found that three of 15 patients with
positivity for SOX2 and/or anti-human antibodies pre-
sented with ipilimumab-related G3 or higher neurolog-
ical toxicity compared with none of 23 patients with
negativity for these antibodies (p ¼ 0.054). One of these
patients had more than one positive antineuronal auto-
antibody (anti-SOX2 and purkinje cell cytoplasmic anti-
body type 1).
Discussion
In our trial, we observed substantial excess toxicity
from the combination ICE, which made the delivery of
the chemoimmunotherapy and the maintenance ipili-
mumab challenging. Delays were frequent, as were in-
terruptions of treatment due to toxicity.
Ipilimumab has a well-deﬁned toxicity proﬁle, and
combination treatments have shown increased toxicity
when compared with monotherapy. In the current study,
the rate of G3 or higher toxicity is considerably higher
(69%) (including ﬁve-related deaths). These ﬁgures are
signiﬁcantly higher than the toxicity reported in the
randomized trial by Reck et al.,22 ranging from 43% to
50% (one toxic death in the concurrent arm). This
increased toxicity might be explained by the better
tolerance of the chemotherapy regimen used in that
study and might also reﬂect excess toxicity from
combining ipilimumab and etoposide. Combining a third
drug (i.e., sunitinib or thalidomide) with the platinum
and etoposide doublet in advanced SCLC has been
Table 4. Summary of Grade 3 or Higher Toxicities in Patients Receiving at Least One Cycle of Ipilimumab (n ¼ 39)
Toxicity Total Ipilimumaba Carboplatina Etoposidea
Patients with at least one grade 3 or higher AE 35 (89.7%) 27 (69.2%) 25 (64.1%) 25(64.1%)
Neurological
Generalized muscle weakness 1 (2.6%) 1 (2.6%) 0 0
Headache 1 (2.6%) 1 (2.6%) 0 0
Agitation 1 (2.6%) 1 (2.6%) 0 0
Nervous system disorder 1 (2.6%) 1 (2.6%) 0 0
Central neuropathy 1 (2.6%) 1 (2.6%) 0 0
Other immune related
ALT increase/transaminitis 3 (7.7%) 3 (7.7%) 0 0
Alkaline phosphatase increase 3 (7.7%) 3 (7.7%) 0 0
Autoimmune disorder 2 (5.1%) 2 (5.1%) 0 0
Colitisb/diarrhea 19 (48.7%) 19 (48.7%) 6 (15.4%) 7 (18%)
Hyperglycemia 2 (5.1%) 1 (2.6%) 1 (2.6%) 1 (2.6%)
Lymphocyte count decrease 2 (5.1%) 0 1 (2.6%) 1 (2.6%)
Neutrophil count decrease 9 (23.1%) 2 (5.1%) 8 (20.5%) 8 (20.5%)
Rash 1 (2.6%) 1 (2.6%) 0 0
Thrombocytopenia 2 (5.1%) 1 (2.6%) 2 (5.1%) 2 (5.1%)
Other
Anemia 6 (15.4%) 0 6 (15.4%) 6 (15.4%)
Dyspnea 3 (7.7%) 1 (2.6%) 1 (2.6%) 1 (2.6%)
Fatigue 3 (7.7%) 1 (2.6%) 2 (5.1%) 2 (5.1%)
Febrile neutropenia 3 (7.7%) 0 2 (5.1%) 2 (5.1%)
Hyponatremia 3 (7.7%) 0 1 (2.6%) 0
Infection 11 (28.2%) 3 (7.7%) 7 (18%) 7 (18%)
Sepsis 4 (10.3%) 2 (5.1%) 2 (5.1%) 2 (5.1%)
Thromboembolic event 2 (5.1%) 2 (5.1%) 2 (5.1%) 2 (5.1%)
aToxicities assessed by site principal investigator to be deﬁnitely, probably, or possibly related to the study drug.
bOne case of ileitis is included.
AE, adverse event; ALT, alanine transaminase.
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protocols have been amended to pursue a maintenance
strategy.6 Moreover, the dose used in this study (10
mg/kg) was higher than the dose currently approved for
melanoma (3 mg/kg), and data suggest increased
toxicity with higher doses.28 Therefore, using ipilimumab
at 3 mg/kg might be more appropriate in combination as
well as in a sequential approach of immunotherapy after
chemotherapy. Newer agents, such as anti–programmed
cell death-1 (anti–PD-1)/anti–programmed death ligand-
1 drugs, with a more favorable toxicity proﬁle might be
easier to combine with chemotherapy. Moreover, ipili-
mumab in combination with the anti–PD-1 agent nivo-
lumab seems to have an acceptable toxicity proﬁle and
added clinical beneﬁt in early-phase testing in patients
with SCLC.29
In our study, the rate of G3 or higher ipilimumab-
related neurological toxicity was 7.6%. A comprehen-
sive study of the prevalence of neurological PNS in a
similar population of patients with SCLC observed that
9.1% had a PNS by clinical evaluation,30 with most of
them (83%) having symptoms preceding the diagnosis of
SCLC. Patients with clinical evidence of autoimmunity
were however excluded from our study. As neurological
toxicities developed after treatment initiation, they aremost likely treatment related. Autoimmunity to the
intracellular antigens SOX2 and Hu has been associated
with PNS in several publications.30–33 Our exploratory
analysis revealed an association between anti-SOX2 and
anti-Hu autoantibodies and severe neurological toxic-
ities. Among patients with anti-SOX2 or anti-Hu anti-
bodies at baseline we could not ﬁnd differences (in
antibody titers or subsequent antibody levels
[Supplementary Fig. 2]) between those in whom neuro-
logical syndromes did and did not develop. The absence
of antineuronal autoantibodies at diagnosis might
therefore reﬂect a decreased likelihood of development
of severe neurological toxicities triggered by ipilimumab.
This suggests that careful monitoring of neurological
symptoms in patients with antineuronal autoantibodies
at baseline is important if immunotherapy is chosen as a
strategy. We recognize that these ﬁndings need further
validation and may additionally reﬂect the particular
method of action of ipilimumab.
Our study is not randomized and therefore we cannot
rule out that the neurological syndromes we clinically
attributed to ipilimumab might have happened regard-
less of treatment with this drug. In two of the three
patients with severe neurological toxicity mimicking
PNS, the onset of the neurological syndrome preceded
September 2016 Ipilimumab, Carboplatin, Etoposide in SCLC 1519and perhaps therefore heralded disease progression. In
the remaining case the progression was observed before
the PNS. Thus, it remains possible that in spite of the
absence of PNS at primary diagnosis, the neurological
syndrome after treatment was caused by progression-
related cross-reactive immune responses.
Markers of the function of regulatory T cells (Tregs)
are lower in patients with autoantibodies and concomi-
tant PNS as compared with in those with no neurological
syndromes.34 Tregs express high levels of CTLA-4 and
are down-regulated or removed by ipilimumab, and this
is a desirable effect to enhance immune response against
the tumor.35,36 Our data are consistent with the hy-
pothesis that downregulation of Tregs in patients with
antineuronal autoantibodies by ipilimumab could pro-
mote development of autoimmune PNS.
The primary end point of the study was not met.
Median PFS was 6.9 months. Interestingly, although
irPFS seems to better reﬂect the efﬁcacy of immuno-
therapeutic agents, in our study both parameters gave
similar results (median irPFS 7.3 months). These results
are consistent with the 6.4-month median irPFS
observed in the phased ipilimumab arm in the study of
Reck et al.22 Four patients with PD according to RECIST
criteria were classiﬁed as being responders or having
stable disease according to irRC. In cases involving other
tumor types, patients with RECIST-deﬁned PD but irRC-
deﬁned response or stable disease seem to have a better
outcome than do those with PD according to both pa-
rameters.37 There is no previous assessment of this
question in SCLC. Because of the low numbers, we were
not able to compare survival of these patients with that
of the RECIST responders.
A key secondary end point was OS. Although this
study involved a relatively small cohort and it cannot be
directly compared with other studies, the median OS of
17 months exceeds the OS reported in other recent trials
in this setting6,22 which is approximately 14 months.
Interestingly, this happened despite the low rate of pa-
tients receiving PCI or thoracic radiotherapy (24%).
Fifty-six percent of the patients were alive at 1 year, 29%
were alive at 2 years, and almost 10% were alive at 3
years. This is consistent with ﬁndings in other studies in
which improved OS is the key beneﬁt from ipilimumab.19
More deﬁnitive data about the potential beneﬁt of this
combination will be available from the completed ran-
domized trial (NCT 01450761).
To investigate potential biomarkers of beneﬁt, we
evaluated the association between autoimmunity and
outcomes. We observed that a positive autoimmune
proﬁle at baseline predicted better response, irPFS with
a trend to increased survival. The presence of autoanti-
bodies at baseline has been linked to prognosis in this
disease with conﬂicting results.31,33,38–40 Overall, there isevidence of patients beneﬁting from naturally occurring
tumor immunity, with improved responses to tumor
treatment or, in rare cases, complete eradication of tu-
mor without tumor treatment.41–43
This would be consistent with our results suggesting
that a preexisting immune response enhanced by ipili-
mumab could result in a beneﬁcial effect from this drug.
Although interesting, these results are hypothesis
generating and need further validation. Moreover, the
lack of a control chemotherapy-only arm precludes us
from demonstrating a predictive versus a merely prog-
nostic role.
In conclusion, ICE as ﬁrst-line treatment for SCLC
shows beneﬁcial effects, particularly in patients with
preexisting autoimmunity. However, toxicity was signif-
icant, suggesting that sequential immunotherapy after
chemotherapy might be a more feasible approach, maybe
in combination with other immune modulators such as
PD-1 or programmed death ligand-1 inhibitors. More
work is needed to demonstrate whether autoantibodies
can serve as biomarkers for toxicity.Acknowledgments
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